Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Inhibits human amidolytic and kininogenase activities of tissue kallikrein. De plus, nous expédions serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 4 Anticorps (65) et serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 4 Protéines (6) et beaucoup plus de produits pour cette protéine.
Showing 2 out of 19 products:
KBP reduces expression of VEGF (Montrer VEGFA Kits ELISA) and HIF-1alpha (Montrer HIF1A Kits ELISA) nuclear translocation
generated a meta-marker model made up of SERPINA4 and PON1 (Montrer PON1 Kits ELISA) that is useful as a differential diagnostic biomarker differentiating lung cancer from other lung diseases.
Our results indicate that during severe sepsis and septic shock, a decrease in plasma concentrations of kallistatin reflects increased severity and poorer outcome of disease.
data suggest that overexpression of kallistatin interferes with lymphopoiesis, ultimately impacting the level of circulating CD19 (Montrer CD19 Kits ELISA)(+) B lymphocytes.
Kallistatin levels were correlated with some markers of systemic inflammation in the HIV population.
Increased kallistatin levels in type 1 diabetes and its relation with carotid intima media thickness may reflect vascular dysfunction and suggest a link between micro- and macro-angiopathy.
reveal novel mechanisms of kallistatin in inducing apoptosis and autophagy in breast cancer cells
crystal structure of kallistatin 1.9 A resolution
Kallistatin protects against renal ischemia-reperfusion injury by blocking oxidative stress and renal inflammation.
Kallistatin's heparin-binding site is crucial for preventing TGF-beta (Montrer TGFB1 Kits ELISA)-induced miR (Montrer MLXIP Kits ELISA)-21 and oxidative stress, while its active site is key for stimulating the expression of eNOS (Montrer NOS3 Kits ELISA).
Plasma kallistatin is a novel marker for severe community-acquired pneumonia prognosis.
Inhibits human amidolytic and kininogenase activities of tissue kallikrein. Inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein.
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4
, serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4
, kallikrein inhibitor
, peptidase inhibitor 4
, protease inhibitor 4 (kallistatin)
, serpin A4